Thanks, House. I'm also wondering if they are required or allowed to PR such news in the middle of the trial. Since it's an open-label trial, I wouldn't see why not.

The protocol has been published at clinicaltrials.gov. I noticed that they did not exclude patients with the Delta 32 mutation (single or double allele). I wonder if this is a mistake -- ? Would be happy to if anyone with a better understanding of Leron's MOA eased my mind.